Breast Cancer Chemoprevention—Can We Make a Case for Precision Medicine? M Daly et al, JAMA Oncology, September 3, 2019

Main|Search|PHGKB




Last Posted: Sep 04, 2019

---

• Breast Cancer Chemoprevention—Can We Make a Case for Precision Medicine?
  M Daly et al, JAMA Oncology, September 3, 2019
• CHIPing away at breast cancer
  AS Sperling, JNCI, August 2019
• Medications to Reduce Breast Cancer Risk-Promise and Limitations
  LE Pace et al, JAMA, September 3, 2019
• Medication Use to Reduce Risk of Breast Cancer- US Preventive Services Task Force Recommendation Statement
  USPSTF Recommendation, JAMA, September 3, 2019
• Pathogenic Germline Variants in Patients With Metastatic Breast Cancer.
  Stuttgen Kelsey et al. JAMA oncology 2019 Aug
• Dual-mode artificially-intelligent diagnosis of breast tumours in shear-wave elastography and B-mode ultrasound using deep polynomial networks.
  Zhang Qi et al. Medical engineering & physics 2019 641-6
• Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
  Terkelsen Thorkild et al. Familial cancer 2019 Aug
• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
  Nelson Heidi D et al. JAMA 2019 322(7) 666-685
• Risk versus benefit of chemoprevention among raloxifene and tamoxifen users with a family history of breast cancer.
  Anderson Chelsea et al. Cancer prevention research (Philadelphia, Pa.) 2019 Aug
• US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.
  Newman Lisa et al. JAMA surgery 2019 Aug

more